<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874936</url>
  </required_header>
  <id_info>
    <org_study_id>SO_SH_01_2019</org_study_id>
    <secondary_id>2019_000402_30</secondary_id>
    <nct_id>NCT03874936</nct_id>
  </id_info>
  <brief_title>The Effect of Perioperative Dexamethasone Administration on Postoperative Pain in Patients Undergoing Periacetabular Osteotomy.</brief_title>
  <acronym>PAODEX</acronym>
  <official_title>The Effect of Perioperative Dexamethasone Administration on Postoperative Pain in Patients Undergoing Periacetabular Osteotomy: A Randomised Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense Patient Data Explorative Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated, Danish mono-center, randomized, placebo-controlled,&#xD;
      parallel group, double-blind, superiority trial of dexamethasone on postoperative pain&#xD;
      management on patients undergoing operation for hip dysplasia with the periacetabular&#xD;
      osteotomy procedure (PAO). 90 adults undergoing PAO will be enrolled.&#xD;
&#xD;
      The primary outcome is to compare the effect of dexamethasone relative to placebo on&#xD;
      cumulated postoperative morphine consumption at 48 hours.&#xD;
&#xD;
      Key secondary outcomes include comparing the effect of repeated doses of dexamethasone&#xD;
      relative to a single dose on cumulated postoperative morphine consumption at 48 hours, and to&#xD;
      determine if dexamethasone is superior to placebo for: Perception of pain intensity,&#xD;
      prevalence and degree of postoperative nausea and vomiting, and patient-reported outcome&#xD;
      measures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulated postoperative morphine consumption in milligrams after 48 hours.</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Morphine administered both as patient-controlled analgesia (PCA) i.v. morphine and any other supplemental morphine administered postoperatively. Consumption in mg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain intensity after 48 hours.</measure>
    <time_frame>24, 48 hours postoperatively</time_frame>
    <description>Pain is evaluated at rest and under the timed-up-and-go (TUG) procedure. Pain intensity is assessed using the visual analogue scale (VAS) (0-100mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulated postoperative morphine consumption from 48 hours until day 14 post operation</measure>
    <time_frame>48 hours - day 14 postoperatively</time_frame>
    <description>Morphine consumption in milligrams after the operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>24 and 48 hours postoperatively</time_frame>
    <description>Nausea and vomiting are evaluated using a 4 point scale: none, mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiemetic consumption</measure>
    <time_frame>0-48 hours postoperatively</time_frame>
    <description>Evaluation of cumulated antiemetic consumption in mg and drug will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>0-7 days postoperatively</time_frame>
    <description>Sleep quality will be assessed using the VAS scale (0-100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed up and go test</measure>
    <time_frame>24, 48 hours postoperatively</time_frame>
    <description>Is assessed from; the time that the participant takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAE)</measure>
    <time_frame>0-8 weeks after operation</time_frame>
    <description>SAE's including wound infection treated with antibiotics or revision. Patients will be asked for SAE during the intervention period, at a follow-up visit 8 weeks the operation. This will be supplemented with a look up for prescriptions.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cumulated postoperative morphine consumption in milligrams after 24hours.</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>Morphine administered both as patient-controlled analgesia (PCA) i.v. morphine and any other supplemental morphine administered postoperatively. Consumption in mg.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cumulated antiemetic consumption</measure>
    <time_frame>0-24 hours postoperatively</time_frame>
    <description>antiemetic consumption in mg and drug will be assessed after 24hrs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>0 hours, 6 hours, 24 hours, 48 hours (72 hours)</time_frame>
    <description>assessment of fasting blood glucose in mg/mL</description>
  </other_outcome>
  <other_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>0, 6, 24, 48 hours (72 hours) postoperatively</time_frame>
    <description>blood sample to evaluate the influence of dexamethasone on the postoperative inflammation development.</description>
  </other_outcome>
  <other_outcome>
    <measure>Leucocytes</measure>
    <time_frame>0, 6, 24, 48 hours (72 hours) postoperatively</time_frame>
    <description>blood sample to evaluate the influence of dexamethasone on the postoperative inflammation development.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cytokines</measure>
    <time_frame>0, 6, 24, 48 hours (72 hours) postoperatively</time_frame>
    <description>evaluate the decrease of cytokines concentration (Interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF) and pentraxin 3 (PTX3) as markers of response during treatment with Dexamethasone</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported outcome measure, quality of life</measure>
    <time_frame>3, 6, 12 months postoperatively</time_frame>
    <description>Based on the questionnaire: EuroQol - 5 Dimensions (EQ-5D) after 3 and 6 months and 1 year follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported outcome measures, health</measure>
    <time_frame>3, 6, 12 months postoperatively</time_frame>
    <description>Patient evaluated health based on the questionnaire: University of California, Los Angeles (UCLA) after 3 and 6 months and 1 year follow up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported outcome measures, the Oxford Hip questionnaire</measure>
    <time_frame>3, 6, 12 months postoperatively</time_frame>
    <description>Patient evaluated activity and pain, based on the questionnaire: Oxford Hip after 3 and 6 months and 1 year follow up.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dexamethasone</condition>
  <condition>Hip Dysplasia</condition>
  <condition>Postoperative Pain</condition>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>A; Dexamethasone twice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24mg intravenous Dexamethasone (Dexavital®, Vital Pharma) 4mg/ml just before the operation and repeated after 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B; Dexamethasone once</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24mg intravenous Dexamethasone just before the operation and placebo which is 6ml of isotonic sodium chloride (9mg/ml, 'normal' saline) after 24 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C; Placebo twice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo intravenous just before the operation and repeated after 24 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 24mg Solution for Injection</intervention_name>
    <description>Administrated i.v.</description>
    <arm_group_label>A; Dexamethasone twice</arm_group_label>
    <arm_group_label>B; Dexamethasone once</arm_group_label>
    <other_name>Dexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Solution for Injection</intervention_name>
    <description>administrated i.v.</description>
    <arm_group_label>B; Dexamethasone once</arm_group_label>
    <arm_group_label>C; Placebo twice</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing PAO due to symptomatic hip dysplasia (CE&lt;25grader) or retroverted&#xD;
             acetabulum (crossover and posterior wall sign)&#xD;
&#xD;
          -  ≥ 18 years&#xD;
&#xD;
          -  Females if fertile: Verified negative human chorionic gonadotropin (HCG), usage of&#xD;
             safe contraceptives or surgical sterilisation.&#xD;
&#xD;
          -  Patients who give their written informed consent to participating in the trial, after&#xD;
             having fully understood the content of the protocol and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who cannot speak or understand Danish&#xD;
&#xD;
          -  Allergy or contraindications to trial medication&#xD;
&#xD;
          -  Spinal anaesthesia&#xD;
&#xD;
          -  Second intervention carried out simultaneously (e.g. femur osteotomy)&#xD;
&#xD;
          -  Patients with daily opioid consumption prior to surgery (tramadol and codeine&#xD;
             accepted)&#xD;
&#xD;
          -  Drug, medical abuse or weekly alcohol consumption beyond ≥7 (female) and ≥14 (men)&#xD;
             units, respectively.&#xD;
&#xD;
          -  Mental disability, anxiety disorder (active psychiatric disorder or consumption of&#xD;
             tricyclic antidepressants)&#xD;
&#xD;
          -  Diabetes diagnosed prior to inclusion&#xD;
&#xD;
          -  Immune suppression therapy (e.g. systemic glucocorticoids)&#xD;
&#xD;
          -  Kidney impairment (eGFR &lt; 50ml/min) or liver disease (≥Child Pugh B)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Søren Overgaard, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Dept. of Orthopaedic Surgery, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stine Hebsgaard, MD</last_name>
    <phone>26814697</phone>
    <phone_ext>+45</phone_ext>
    <email>stine.hebsgaard3@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Viktoria Lindberg-Larsen, MD, PhD</last_name>
    <phone>28791991</phone>
    <phone_ext>+45</phone_ext>
    <email>viktoria.lindberg-larsen@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viktoria Lindberg-Larsen, MD, PhD</last_name>
      <phone>28791991</phone>
      <phone_ext>+45</phone_ext>
      <email>viktoria.lindberg-larsen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Viktoria Lindberg-Larsen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stine Hebsgaard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Stine Hebsgaard</investigator_full_name>
    <investigator_title>medical doctor, principal investigator</investigator_title>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>pain management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hip Dislocation</mesh_term>
    <mesh_term>Developmental Dysplasia of the Hip</mesh_term>
    <mesh_term>Hip Dislocation, Congenital</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

